Is Intellia Therapeutics Inc (NASDAQ: NTLA) No Longer A Good Investment?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

NTLA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $27.47 and fluctuated between $27.90 as its day high and $26.01 as its day low. The current market capitalization of Intellia Therapeutics Inc is $2.46B. A total of 1.22 million shares were traded on the day, compared to an average of 1.55M shares.

Insider Activity

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, NTLA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 6 SELLs from insiders. Insiders purchased 313,877 shares during that period but sold 8,845.

In the most recent transaction, Sepp-Lorenzino Laura sold 2,275 shares of NTLA for 28.87 per share on Jan 08. After the transaction, the EVP, Chief Scientific Officer now owns 43,927 company shares. In a previous transaction on Jan 03, LEONARD JOHN M sold 19,223 shares at 29.46 per share. NTLA shares that President and CEO owns now total 846,486.

Among the insiders who sold shares, Lebwohl David disposed of 5,843 shares on Jan 03 at a per-share price of $29.46. This resulted in the EVP, Chief Medical Officer holding 54,372 shares of NTLA after the transaction. In another insider transaction, Sepp-Lorenzino Laura sold 5,532 shares at $29.46 per share on Jan 03. Company shares held by the EVP, Chief Scientific Officer now total 46,202.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for NTLA in the last 3 months, the mean price target is $75.71 with high estimates of $145.00 and low estimates of $29.00. In terms of 52-week highs and lows, NTLA has a high of $47.48 and a low of $22.67.

As of this writing, NTLA has an earnings estimate of -$1.45 per share for the current quarter. EPS was calculated based on a consensus of 23 estimates, with a high estimate of -$1.01 per share and a lower estimate of -$1.65. The company reported an EPS of -$1.4 in the last quarter, which was -6.10% lower than expectations of -$1.32.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. NTLA’s latest balance sheet shows that the firm has $748.69M in Cash & Short Term Investments as of fiscal 2021. There were $74.02M in debt and $125.83M in liabilities at the time. Its Book Value Per Share was $11.64, while its Total Shareholder’s Equity was $1.04B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NTLA is Buy with a score of 4.60.

Most Popular

Related Posts